Jaume Pons, ALX Oncology CEO
November 1, 2022 11:23 AM EDTUpdated 11:35 AM
Financing
R&D

Bet­ting on CD47 as oth­ers ditch the tar­get, ALX bor­rows up to $100M to push sole clin­i­cal drug for­ward

Lei Lei Wu

News Reporter

At its peak, ALX On­col­o­gy $ALXO was trad­ing at $88 per share, rid­ing on the promise of block­ing CD47, which can­cer cells use to broad­cast …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times